Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130
Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

177
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
177

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lymphocyte alterations and elevated complement signaling are key features of refractory myasthenia gravis.

Med (New York, N.Y.)·2026
Same author

Frequent co-occurrence of AChR-positive myasthenia gravis in facioscapulohumeral muscular dystrophy suggests a novel disease association.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Orthostatic tremor and its subtypes: a single centre cohort of 74 patients.

Journal of neurology·2026
Same author

Rehabilitation Guidelines in Stroke.

British journal of hospital medicine (London, England : 2005)·2025
Same author

Lecanemab appropriate use recommendations for clinical practice in the UK.

Journal of neurology, neurosurgery, and psychiatry·2025
Same author

Machine learning detects hidden treatment response patterns only in the presence of comprehensive clinical phenotyping.

PloS one·2025
Same journal

Who I am affects what I do.

Practical neurology·2026
Same journal

Recurrent falls while taking clozapine.

Practical neurology·2026
Same journal

Anti-Ma2 encephalitis: when the examination localises beyond MRI.

Practical neurology·2026
Same journal

Oculopharyngeal muscular dystrophy: diagnosis, management and multisystem care.

Practical neurology·2026
Same journal

Neurological signs of possible diagnostic value in the cognitive clinic: past, present and future.

Practical neurology·2026
Same journal

Longitudinally extensive myelitis in neurosarcoidosis.

Practical neurology·2026
See all related articles

Related Experiment Video

Updated: Jun 24, 2025

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.0K

Methotrexate for the neurologist.

Aaron Jesuthasan1, Aravindhan Baheerathan2, Stephen Auger2

  • 1Department of Neurology, Addenbrooke's Hospital, Cambridge, UK aaronjesuthasan@gmail.com.

Practical Neurology
|May 31, 2024
PubMed
Summary
This summary is machine-generated.

Methotrexate is a versatile drug used for cancer and inflammatory conditions like rheumatoid arthritis. This review covers its use in neurological diseases, focusing on safe application and monitoring.

Keywords:
CLINICAL NEUROLOGYMUSCLE DISEASENEUROIMMUNOLOGYNEUROMUSCULAR

More Related Videos

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

2.6K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

39.7K

Related Experiment Videos

Last Updated: Jun 24, 2025

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.0K
Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

2.6K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

39.7K

Area of Science:

  • Neurology
  • Pharmacology
  • Immunology

Background:

  • Methotrexate use has expanded beyond chemotherapy to treat inflammatory diseases.
  • It serves as a steroid-sparing agent for various neurological inflammatory conditions.
  • Clinical neurologists require guidance on methotrexate's practical application.

Purpose of the Study:

  • To review the evidence for methotrexate in neurological diseases.
  • To discuss practical aspects of methotrexate use, including initiation, titration, monitoring, and toxicity.

Main Methods:

  • Literature review of studies on methotrexate in neurological conditions.
  • Synthesis of clinical guidelines and evidence for practical application.

Main Results:

  • Evidence supports methotrexate for specific neurological inflammatory diseases.
  • Practical considerations for safe initiation, titration, and monitoring are outlined.
  • Potential toxicities and management strategies are discussed.

Conclusions:

  • Methotrexate is a valuable treatment option for select neurological disorders.
  • Understanding its evidence base and practicalities is crucial for safe and effective clinical use.